Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
AstraZeneca PLC
Bear Case (25th pct.)
-18.8% vs price
Base Case (Median)
8.6% vs price
Bull Case (75th pct.)
38.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $203.29 | 61.9% | High (40%) |
| PE Comparable | $144.51 | 15.1% | Medium (25%) |
| Growth Trajectory DCF | $277.79 | 121.2% | Medium (20%) |
| Graham Number | $67.97 | -45.9% | Medium (40%) |
| EV/EBITDA | $81.13 | -35.4% | Medium (20%) |
| EV/FCF | $136.38 | 8.6% | Medium (20%) |
| Earnings Power Value | $122.83 | -2.2% | Medium (50%) |
Based on 7 out of 7 methods, AZNCF appears fairly valued at the current price of $125.58. The base case fair value of $136.38 implies 8.6% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.